Ebola Treatment Trial Commences in DRC Amidst Ongoing Outbreak
The World Health Organization (WHO) has announced the start of a clinical trial in the Democratic Republic of Congo (DRC) to evaluate potential treatments for the strain of Ebola virus responsible for the current deadly outbreak. The first patient has already been enrolled in the study.
Dr. Tedros Adhanom Ghebreyesus, the head of the WHO, stated on Thursday that the trial of two therapeutic candidates has begun. He emphasized that while some individuals are recovering from the disease without approved treatments, safe and effective therapies could significantly reduce the mortality rate.
Current Outbreak and Disease Overview
The current Ebola outbreak, which originated in May, has been declared a public health emergency by the WHO. As of June 30, the DRC has reported 1,406 confirmed cases, 301 suspected cases, and 438 deaths. Additionally, Uganda has confirmed 20 cases with two fatalities, and one case has been identified in France as of July 1.
This particular outbreak is caused by the Bundibugyo strain of the Ebola virus, for which no approved vaccines or treatments currently exist. Ebola is a highly infectious disease that attacks the body's immune system and organs. While it typically infects animals, such as fruit bats, human outbreaks can occur through contact with infected animals.
Trial Collaboration and Development
The clinical trial is being sponsored by the WHO and is a collaborative effort coordinated by scientists from the Institut National de Recherche Biomédicale in the DRC, the Institute of Tropical Medicine in Belgium, and the University of Oxford in the United Kingdom.
Symptoms of Ebola usually appear suddenly, typically between two and 21 days after exposure. Initial symptoms often resemble the flu or malaria, including fever, headache, and fatigue. Individuals generally become contagious only after symptoms manifest. There are six known species of Ebola, but only three are known to cause human outbreaks, and specific vaccines must be developed for each.
Source: Original Article
